Pediatric psoriasis comorbidity screening guidelines

Emily Osier, Audrey S. Wang, Megha M. Tollefson, Kelly M. Cordoro, Stephen R. Daniels, Andrew Eichenfield, Joel M. Gelfand, Alice B. Gottlieb, Alexa B. Kimball, Mark Lebwohl, Nehal N. Mehta, Amy S. Paller, Jeffrey B. Schwimmer, Dennis M. Styne, Abby S. Van Voorhees, Wynnis L. Tom, Lawrence F. Eichenfield

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

IMPORTANCE Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. OBJECTIVE To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. EVIDENCE REVIEW A literature review was performed using PubMed from January 1999 through December 2015. Limiting the search to human studies published in English and removing reviews and editorials produced 153 relevant manuscripts. An expert panel in psoriasis, pediatric dermatology, pediatric rheumatology, pediatric gastroenterology, pediatric endocrinology, and adult and pediatric cardiology used the patient-centered Strength of Recommendation Taxonomy (SORT) method to evaluate and grade the quality of evidence. FINDINGS Because of the limited number of pediatric studies published on these topics, the strength of the panel's recommendations is classified as SORT level C expert consensus recommendations. The majority of recommendations coincide with those endorsed by the American Academy of Pediatrics for the general pediatric patient but with added attention to signs and symptoms of arthritis, depression, and anxiety. The panel also identified key areas for further investigation. CONCLUSIONS AND RELEVANCE Patients with pediatric psoriasis should receive routine screening and identification of risk factors for associated comorbidities. These guidelines are relevant for all health care providers caring for patients with pediatric psoriasis, including primary care clinicians, dermatologists, and pediatric specialists. Because these are the first pediatric guidelines, re-review and refinement will be necessary as studies further detail, and possibly stratify, risk in affected children.

Original languageEnglish (US)
Pages (from-to)698-704
Number of pages7
JournalJAMA Dermatology
Volume153
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Psoriasis
Comorbidity
Guidelines
Pediatrics
Anxiety
Depression
Psoriatic Arthritis
Manuscripts
Endocrinology
Rheumatology
Gastroenterology
Dyslipidemias
Dermatology
Cardiology
PubMed
Health Personnel
Type 2 Diabetes Mellitus
Signs and Symptoms
Arthritis
Primary Health Care

ASJC Scopus subject areas

  • Dermatology

Cite this

Osier, E., Wang, A. S., Tollefson, M. M., Cordoro, K. M., Daniels, S. R., Eichenfield, A., ... Eichenfield, L. F. (2017). Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatology, 153(7), 698-704. https://doi.org/10.1001/jamadermatol.2017.0499

Pediatric psoriasis comorbidity screening guidelines. / Osier, Emily; Wang, Audrey S.; Tollefson, Megha M.; Cordoro, Kelly M.; Daniels, Stephen R.; Eichenfield, Andrew; Gelfand, Joel M.; Gottlieb, Alice B.; Kimball, Alexa B.; Lebwohl, Mark; Mehta, Nehal N.; Paller, Amy S.; Schwimmer, Jeffrey B.; Styne, Dennis M.; Van Voorhees, Abby S.; Tom, Wynnis L.; Eichenfield, Lawrence F.

In: JAMA Dermatology, Vol. 153, No. 7, 01.07.2017, p. 698-704.

Research output: Contribution to journalReview article

Osier, E, Wang, AS, Tollefson, MM, Cordoro, KM, Daniels, SR, Eichenfield, A, Gelfand, JM, Gottlieb, AB, Kimball, AB, Lebwohl, M, Mehta, NN, Paller, AS, Schwimmer, JB, Styne, DM, Van Voorhees, AS, Tom, WL & Eichenfield, LF 2017, 'Pediatric psoriasis comorbidity screening guidelines', JAMA Dermatology, vol. 153, no. 7, pp. 698-704. https://doi.org/10.1001/jamadermatol.2017.0499
Osier E, Wang AS, Tollefson MM, Cordoro KM, Daniels SR, Eichenfield A et al. Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatology. 2017 Jul 1;153(7):698-704. https://doi.org/10.1001/jamadermatol.2017.0499
Osier, Emily ; Wang, Audrey S. ; Tollefson, Megha M. ; Cordoro, Kelly M. ; Daniels, Stephen R. ; Eichenfield, Andrew ; Gelfand, Joel M. ; Gottlieb, Alice B. ; Kimball, Alexa B. ; Lebwohl, Mark ; Mehta, Nehal N. ; Paller, Amy S. ; Schwimmer, Jeffrey B. ; Styne, Dennis M. ; Van Voorhees, Abby S. ; Tom, Wynnis L. ; Eichenfield, Lawrence F. / Pediatric psoriasis comorbidity screening guidelines. In: JAMA Dermatology. 2017 ; Vol. 153, No. 7. pp. 698-704.
@article{d1577bdce7f246b5bbc5b260ab34d5af,
title = "Pediatric psoriasis comorbidity screening guidelines",
abstract = "IMPORTANCE Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. OBJECTIVE To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. EVIDENCE REVIEW A literature review was performed using PubMed from January 1999 through December 2015. Limiting the search to human studies published in English and removing reviews and editorials produced 153 relevant manuscripts. An expert panel in psoriasis, pediatric dermatology, pediatric rheumatology, pediatric gastroenterology, pediatric endocrinology, and adult and pediatric cardiology used the patient-centered Strength of Recommendation Taxonomy (SORT) method to evaluate and grade the quality of evidence. FINDINGS Because of the limited number of pediatric studies published on these topics, the strength of the panel's recommendations is classified as SORT level C expert consensus recommendations. The majority of recommendations coincide with those endorsed by the American Academy of Pediatrics for the general pediatric patient but with added attention to signs and symptoms of arthritis, depression, and anxiety. The panel also identified key areas for further investigation. CONCLUSIONS AND RELEVANCE Patients with pediatric psoriasis should receive routine screening and identification of risk factors for associated comorbidities. These guidelines are relevant for all health care providers caring for patients with pediatric psoriasis, including primary care clinicians, dermatologists, and pediatric specialists. Because these are the first pediatric guidelines, re-review and refinement will be necessary as studies further detail, and possibly stratify, risk in affected children.",
author = "Emily Osier and Wang, {Audrey S.} and Tollefson, {Megha M.} and Cordoro, {Kelly M.} and Daniels, {Stephen R.} and Andrew Eichenfield and Gelfand, {Joel M.} and Gottlieb, {Alice B.} and Kimball, {Alexa B.} and Mark Lebwohl and Mehta, {Nehal N.} and Paller, {Amy S.} and Schwimmer, {Jeffrey B.} and Styne, {Dennis M.} and {Van Voorhees}, {Abby S.} and Tom, {Wynnis L.} and Eichenfield, {Lawrence F.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1001/jamadermatol.2017.0499",
language = "English (US)",
volume = "153",
pages = "698--704",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Pediatric psoriasis comorbidity screening guidelines

AU - Osier, Emily

AU - Wang, Audrey S.

AU - Tollefson, Megha M.

AU - Cordoro, Kelly M.

AU - Daniels, Stephen R.

AU - Eichenfield, Andrew

AU - Gelfand, Joel M.

AU - Gottlieb, Alice B.

AU - Kimball, Alexa B.

AU - Lebwohl, Mark

AU - Mehta, Nehal N.

AU - Paller, Amy S.

AU - Schwimmer, Jeffrey B.

AU - Styne, Dennis M.

AU - Van Voorhees, Abby S.

AU - Tom, Wynnis L.

AU - Eichenfield, Lawrence F.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - IMPORTANCE Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. OBJECTIVE To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. EVIDENCE REVIEW A literature review was performed using PubMed from January 1999 through December 2015. Limiting the search to human studies published in English and removing reviews and editorials produced 153 relevant manuscripts. An expert panel in psoriasis, pediatric dermatology, pediatric rheumatology, pediatric gastroenterology, pediatric endocrinology, and adult and pediatric cardiology used the patient-centered Strength of Recommendation Taxonomy (SORT) method to evaluate and grade the quality of evidence. FINDINGS Because of the limited number of pediatric studies published on these topics, the strength of the panel's recommendations is classified as SORT level C expert consensus recommendations. The majority of recommendations coincide with those endorsed by the American Academy of Pediatrics for the general pediatric patient but with added attention to signs and symptoms of arthritis, depression, and anxiety. The panel also identified key areas for further investigation. CONCLUSIONS AND RELEVANCE Patients with pediatric psoriasis should receive routine screening and identification of risk factors for associated comorbidities. These guidelines are relevant for all health care providers caring for patients with pediatric psoriasis, including primary care clinicians, dermatologists, and pediatric specialists. Because these are the first pediatric guidelines, re-review and refinement will be necessary as studies further detail, and possibly stratify, risk in affected children.

AB - IMPORTANCE Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. OBJECTIVE To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. EVIDENCE REVIEW A literature review was performed using PubMed from January 1999 through December 2015. Limiting the search to human studies published in English and removing reviews and editorials produced 153 relevant manuscripts. An expert panel in psoriasis, pediatric dermatology, pediatric rheumatology, pediatric gastroenterology, pediatric endocrinology, and adult and pediatric cardiology used the patient-centered Strength of Recommendation Taxonomy (SORT) method to evaluate and grade the quality of evidence. FINDINGS Because of the limited number of pediatric studies published on these topics, the strength of the panel's recommendations is classified as SORT level C expert consensus recommendations. The majority of recommendations coincide with those endorsed by the American Academy of Pediatrics for the general pediatric patient but with added attention to signs and symptoms of arthritis, depression, and anxiety. The panel also identified key areas for further investigation. CONCLUSIONS AND RELEVANCE Patients with pediatric psoriasis should receive routine screening and identification of risk factors for associated comorbidities. These guidelines are relevant for all health care providers caring for patients with pediatric psoriasis, including primary care clinicians, dermatologists, and pediatric specialists. Because these are the first pediatric guidelines, re-review and refinement will be necessary as studies further detail, and possibly stratify, risk in affected children.

UR - http://www.scopus.com/inward/record.url?scp=85024104926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024104926&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2017.0499

DO - 10.1001/jamadermatol.2017.0499

M3 - Review article

C2 - 28514463

AN - SCOPUS:85024104926

VL - 153

SP - 698

EP - 704

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 7

ER -